{
  "context": {
    "rules": [
      "Rule1: Provided that an export license is granted for the drug in the region, or it is not the case that either the drug receives patent approval from the agency or the absence of therapeutic use for the condition leads to a distribution ban on the drug in the region, then generic competition exists for the drug in the market.",
      "Rule2: Whenever a prescription is required for the drug in the region, the drug has therapeutic use for the condition.",
      "Rule3: In the event that the drug is classified as a controlled substance by the agency, a prescription is required for the drug in the region.",
      "Rule4: If the drug is used in hospitals in the region, then the drug is dispensed through pharmacies in the region.",
      "Rule5: Provided that the drug is authorized for emergency use in the region, it is used in hospitals in the region.",
      "Rule6: Whenever the drug is permitted for experimental use in the region, it is authorized for emergency use in the region.",
      "Rule7: Should the region provide research funding for the drug, then if alcohol is approved in the region, the drug has therapeutic use for the condition.",
      "Rule8: Either the region provides research funding for the drug, or a clinical trial is conducted for the drug involving an event.",
      "Rule9: Either an adverse event occurs for the drug involving a patient, or a side effect occurs for the drug involving a patient.",
      "Rule10: If a side effect occurs for the drug involving a patient, then provided that it is not the case that alcohol being approved in the region leads to therapeutic use for the condition, a regulatory investigation is conducted for the drug by the agency.",
      "Rule11: Whenever manufacturing is suspended for the drug at the facility, then if it is not the case that an adverse event occurring for the drug involving a patient implies that the absence of alcohol approval in the region leading to therapeutic use for the condition results in a regulatory investigation for the drug by the agency, a product recall is issued for the drug in the market.",
      "Rule12: Either manufacturing is suspended for the drug at the facility, or production is halted for the drug at the facility.",
      "Rule13: Should production be halted for the drug at the facility, then if it is not the case that an adverse event occurring for the drug involving a patient leads to the scenario where the lack of alcohol approval in the region implying therapeutic use for the condition causes a regulatory investigation for the drug by the agency, a product recall is issued for the drug in the market.",
      "Rule14: If the clinical trial is suspended for the drug, then the drug receives market approval in the region.",
      "Rule15: If the person is part of the research team for the trial, then the person is a co-investigator for the trial.",
      "Rule16: Should the person be a co-investigator for the trial, then if the person is the principal investigator for the trial, then provided that it is not the case that the absence of a clinical trial for the drug involving an event implying that alcohol approval in the region leads to therapeutic use for the condition results in a safety violation for the drug during an event, the clinical trial is suspended for the drug.",
      "Rule17: If an import restriction is placed on the drug in the region, then a distribution ban is imposed on the drug in the region.",
      "Rule18: Whenever international trade occurs for the drug in the region, then export approval is granted for the drug in the region.",
      "Rule19: Either international trade occurs for the drug in the region, or the absence of therapeutic use for the condition leads to an import restriction being placed on the drug in the region.",
      "Rule20: Either recreational use of the drug is legal in the region, or the drug is classified as a controlled substance by the agency.",
      "Rule21: If the drug is restricted to medical use only in the region, then it is not the case that recreational use of the drug is legal in the region.",
      "Rule22: Either the drug is decriminalized in the region, or the drug is restricted to medical use only in the region.",
      "Rule23: Either an age restriction applies to the drug in the region, or a prescription refill is allowed for the drug for the patient.",
      "Rule24: Whenever a prescription refill is allowed for the drug for the patient, then the drug has therapeutic use for the condition.",
      "Rule25: In the event that a medication error occurs for the drug at the facility, then a dispensing error occurs for the drug at the facility.",
      "Rule26: If a manufacturing defect is present for the drug at the facility, then the drug passes quality control at the facility.",
      "Rule27: Provided that a manufacturing defect is present for the drug at the facility, then it is not the case that the drug passes quality control at the facility.",
      "Rule28: Either a manufacturing defect is present for the drug at the facility, or if it is not the case that the absence of a clinical trial for the drug involving an event implying that alcohol approval in the region leads to therapeutic use for the condition results in a safety violation for the drug during an event, then the drug receives market approval in the region.",
      "Rule29: Provided that it is not the case that either the drug is available over the counter in the region or the drug has therapeutic use for the condition, then the drug is compounded at the pharmacy facility.",
      "Rule30: Should it not be the case that either the drug is available over the counter in the region or the drug has therapeutic use for the condition, then it is not the case that the drug is dispensed through pharmacies in the region.",
      "Rule31: If it is not the case that an adverse event occurring for the drug involving a patient implies that the lack of alcohol approval in the region leading to therapeutic use for the condition results in a regulatory investigation for the drug by the agency, then it is not the case that a product recall is issued for the drug in the market.",
      "Rule32: Should it not be the case that a clinical trial being conducted for the drug involving an event leads to alcohol approval in the region implying therapeutic use for the condition, then it is not the case that a safety violation occurs for the drug during an event.",
      "Rule33: Whenever it is not the case that an age restriction applying to the drug in the region implies that the drug is available over the counter in the region, then the drug is approved for pediatric use in the population.",
      "Rule34: Provided that it is not the case that the person being a pharmacist at the facility leads to the scenario where if the drug is compounded at the pharmacy facility, then the drug is dispensed through pharmacies in the region, then a medication error occurs for the drug at the facility.",
      "Rule35: If it is not the case that either the drug receives patent approval from the agency or the lack of therapeutic use for the condition implies a distribution ban on the drug in the region, then it is not the case that generic competition exists for the drug in the market.",
      "Rule36: Provided that it is not the case that the absence of either the drug being available over the counter in the region or the drug having therapeutic use for the condition leads to the drug being permitted for experimental use in the region, then the drug is banned as a substance in the region.",
      "Rule37: Should it not be the case that the drug is classified as a controlled substance by the agency, then the drug is used recreationally by the population.",
      "Rule38: Provided that it is not the case that the drug is classified as a controlled substance by the agency, then it is not the case that the drug is used recreationally by the population.",
      "Rule39: Should the drug not have therapeutic use for the condition, then it is not the case that a distribution ban is imposed on the drug in the region."
    ],
    "facts": [
      "Fact1: Alcohol is approved in the region.",
      "Fact2: The person is the principal investigator for the trial.",
      "Fact3: The person is part of the research team for the trial.",
      "Fact4: The person is a pharmacist at the facility.",
      "Fact5: It is not the case that an export license is granted for the drug in the region.",
      "Fact6: It is not the case that the drug is available over the counter in the region.",
      "Fact7: It is not the case that the drug is banned as a substance in the region.",
      "Fact8: It is not the case that a regulatory investigation is conducted for the drug by the agency.",
      "Fact9: It is not the case that export approval is granted for the drug in the region.",
      "Fact10: It is not the case that the drug is decriminalized in the region.",
      "Fact11: It is not the case that the drug is approved for pediatric use in the population.",
      "Fact12: It is not the case that a dispensing error occurs for the drug at the facility.",
      "Fact13: It is not the case that the drug receives market approval in the region.",
      "Fact14: It is not the case that the drug receives patent approval from the agency."
    ]
  },
  "question": "The drug has therapeutic use for the condition."
}